Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and...
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating...
Valion Bio Appoints Melinda Lackey as General Counsel
Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership Team
Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model ALN1003 also demonstrated reductions in liver weight and improvements...